Dutch health reform at a crossroads by Maarse, J.A.M.
  
 
Dutch health reform at a crossroads
Citation for published version (APA):
Maarse, J. A. M. (2011). Dutch health reform at a crossroads. Health Care Cost Monitor, 2011(June), 1-2.
Document status and date:
Published: 07/06/2011
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 03 Jun. 2020
Dutch Health Reform at a
Crossroads
June 7, 2011
Many health policy watchers follow the Netherlands’s health care
reform experience with great interest. The 2006 reform ended the
traditional dividing line between the sickness fund scheme, which
covered about 67% of the population, and private insurance
covering the rest, and it introduced a single mandatory scheme
carried out by private insurers who may go for profit. These
insurers must cover all legal residents.
The reform is intended to bring about a system of regulated
competition in health care. The aim is to introduce competition
while upholding fundamental social values, in particular solidarity
in health care financing and universal access to health care.
Another aim is to enhance consumer choice. Everyone has the right
to switch insurance providers by the end of the year.
People pay a set annual contribution, which in 2011 was 7.75% of
income for employed persons and 5.65% self-employed persons. To
induce competition, everyone also pays an annual premium set by
each insurer separately, which this year ranged from 1,068 to
1,272 euro. The government pays the premium for children under
18.
Most people (89%) also purchase complementary health insurance
to cover care that is not included in the basic scheme, such as
physiotherapy and some forms of dental care. Insurers of these
policies are not required to accept each applicant. Risk selection is
permitted, but so far it has been quite limited: all insurers have
given priority to the preservation and extension of their market
share.
Is the health insurance reform a success? The answer depends on
the perspective taken. First, the integration of the sickness fund
scheme and private health insurance into a single scheme has
strengthened solidarity. However, the premium charge (including
the employer’s part and the contribution for the exceptional
medical expenses scheme for long-term care) as a percentage of
income is still significantly lower for persons with an income of
100.000 euro than for persons with an income of only 10.000 euro;
the percentages are about 7 and 25% of income respectively. How
to assess these differences in premium charges is of course a
matter of political preference.
Second, although insurance is mandatory, this requirement is not
perceived as a serious restriction of freedom of choice. In fact, the
reform has enhanced freedom of choice because of the yearly
option to switch insurers. This year (2011) consumer mobility is
5.5% versus 3.9% in 2010. However, insurers and subscribers have
only limited freedom regarding the composition of the benefits
package because it is set by the government.
Third, the 2006 reform the number of insurers has dropped by
nearly half from about 57 to 29. However, these figures obscure the
concentrated structure of the health insurance market because four
major companies (Achmea, Menzis, Uvit and Menzis) have a market
share of about 90%, with 20 of the 29 insurers belong to one of
these companies. In some regions the market structure is so
concentrated that it may restrict freedom of choice.
Fourth, it is fair to say that managed care by patient steering and
selective contracting is still in its infancy. So far, insurers have
mainly used soft instruments to influence patients, in particular by
giving them information on the waiting times of hospitals. However,
there are indications of change. Some insurers recently announced
that they will only contract hospitals which meet the quality
standards of care, for instance in the field of breast cancer surgery.
Fifth, one may argue that that the results as regards the reform’s
objective of keeping health care affordable do not point to much
success. From 2006 to 2009 health care expenditures rose by
19.4% compared to 16% over the period 2002–2005 The fraction of 
publicly financed health care in GDP grew from 6.8% in 2002 to
7.1% in 2005 and from 8.5% in 2006 to 9.5% in 2009 (the jump in
2006 is due to the integration of private health insurance into the
basic health insurance scheme). The contribution rate period
increased from 6.5% in 2006 to 7.75% in 2011. Over the same
period the insurer premium rose by about 38%. Even more
problematic is that for the years to come the growth of health care
costs is expected to outstrip the growth of GDP by at least 2% a
year.
More reforms are therefore foreseen for the near future. An
important issue is how to respond to the expected growth of health
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care expenditures. The first and most frequently used strategy is to
raise contributions and premiums. A second strategy is to raise
private payments, for instance by raising the mandatory deductible,
asking more and higher co-payments or reducing coverage by
removing health services from the basic benefits package. This
strategy is politically highly controversial. Private payments have
always been very unpopular politically, which helps explain why the
fraction of private payments in health care financing (9% to 10%) is
low in the Netherlands compared to most European countries. A
third strategy is to spur insurers to negotiate low prices with health
care providers.
The last strategy relates to the government’s strategy in market
reform. The government recently announced a continuation and
acceleration of the market reform. But it also wants to retain the
instrument of fixed budgets to control total expenditures (which
implies that cost overruns must be offset by expenditure cuts the
following year). Thus, the market reform remains to be a political
compromise between the objective of freedom and
entrepreneurship on the one hand and the need for central control
on the other hand. How the market reform and the tension between
freedom and control will evolve in future, is written in the stars of
health care policymaking.
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